Perceptions of caregivers of sick children toward a possible malaria vaccine in Kenya  by Ojakaa, D.I. et al.
432 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
ive for policy makers to include OCV as part of a comprehensive
package to enhance existing water and sanitation initiatives.
http://dx.doi.org/10.1016/j.ijid.2014.03.1310
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Background: Several malaria vaccines are currently in clini-
cal trials and are expected to provide an improved strategy for
malaria control. Prior to introduction of a new vaccine, policy-
makersmust consider the socio-cultural environment of the region
to ensurewidespread community approval. Our study investigated
the acceptability and attitudes of child caregivers toward a malaria
vaccine, and analyzed factors that inﬂuence these.
Methods & Materials: Interviews from a standard question-
naire were conducted with 2,003 caregivers at 695 randomly
selected health facilities across Kenya during the Kenya Service
Provision Assessment Survey 2010. Multinomial regression of
quantitative data was conducted using STATA to analyze the deter-
minants of caregivers accepting malaria vaccination of their child.
Results: Mothers represented 90% of caregivers interviewed as
they brought their child to the health facility, and 77% of caregivers
were 20-34 years old. Overall, 88% of respondents indicated that
they would accept a malaria vaccine, both for a child in their com-
munity and their own child. Approval for a vaccine was highest in
malaria-endemic Nyanza province at 98.9%, and lowest in the sea-
sonal transmission area of North Eastern Kenya at 23%. Although
94% of respondents who had attended at least some schooling
reported acceptance of the vaccine, only 56% of those who had
never attended school would accept the vaccine. The likelihood
of accepting one’s own child to be immunized was signiﬁcantly
associated with region, satisfaction with health care services in
the facility attended, age of the caregiver, and education. Further
regression analysis of the intersection of signiﬁcant variables with
region did not correlate signiﬁcantly.
Conclusion: Our results indicate a need for targeted messages
and education on the malaria vaccine, particularly for residents of
regions where acceptance is low, older caregivers, and those with
low literacy and school-attendance levels. This study provides crit-
ical evidence to inform policy for a new malaria vaccine that will
support its timely and comprehensive uptake in Kenya.
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Best practices in nucleic acid removal from viral
vaccine manufacture
P. Pattnaik, G. Weber ∗
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Background: The production of viral vaccines at commercial
scale requires large quantities of viruses as an antigenic source.
There are different production platforms suitable for viral repli-
cation -mammalian, avian and insect cells. Host cell residuals in
the ﬁnal product - nucleic acid in particular - create a signiﬁcant
concern due to a potential transfer and integration into the liv-
ing cell’s genetic material, potentially leading to various harmful
effects including cancer. Health authorities and regulatory bod-
ies continue to increase safety standards for biopharmaceutical
products, providing stringent guidelines on removal of residual
nucleic acid from the vaccine manufacturing processes. Several
physicochemical methods exist to reduce nucleic acid during the
manufacturing process, each with its unique strengths and weak-
nesses. One of the methods to reduce nucleic acid contaminants is
via enzymatic degradation with endonucleases. It acts on nucleic
acid by speciﬁcally catalyzing the hydrolysis of internal phospho-
diester bonds in DNA and RNA chains breaking them into smaller
nucleotides. Smaller nucleotides/nucleic acid fragments, so also the
endonucleases, can be easily removed from the process during sub-
sequent downstream processing using ultraﬁltration/diaﬁltration
and chromatography. This presentation highlights recent advances
in nucleic acid removal from vaccine processes.
Methods & Materials: Benzonase treatment, Tangential ﬂow
ﬁltration and chromatography
Results: 3 log reduction of DNA removal by TFF coupled with
Benzonase treatment
Conclusion: Complete removal of host cell DNA is feasible by
usingcombinationsofnuclease treatment, tangentialﬂowﬁltration
and chromatography.
http://dx.doi.org/10.1016/j.ijid.2014.03.1312
